Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Myofascial Pain Dysfunction Syndrome
Interventions
DRUG

Magnesium sulphate

After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate

DRUG

Lidocaine (drug)

After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine

DRUG

Saline

After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline

All Listed Sponsors
lead

Misr University for Science and Technology

OTHER

NCT06595017 - Lidocaine Versus Magnesium Sulphate in Management of Myofascial Pain Dysfunction Syndrome | Biotech Hunter | Biotech Hunter